Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Managed Care April 2005	Diabetes Costs Rise, But so Does Adherence A typical health plan can expect endocrine and diabetes agents to amount to 6% to 8% of total utilization costs, with spending on these agents to increase between 11% and 15% 2005.
Managed Care August 2007	Headlines On Deadline ... A survey finds that many employees struggle with basic health benefit terms... Old matches new when it comes to oral diabetes drugs...
The Motley Fool February 4, 2008 Brian Lawler	Best International Stock: Novo Nordisk A quick summary of Danish drugmaker Novo Nordisk, the world's number one manufacturer of diabetes medications.
The Motley Fool October 2, 2009 Brian Orelli	Warning! Potential Blockbuster Ahead It's a little early to call it, but it looks like Bristol-Myers Squibb and AstraZeneca have a potential blockbuster on their hands with their new diabetes drug.
The Motley Fool November 24, 2010 Brian Orelli	Profit From the United States of Diabetes Half the country could have an early form by 2020.
Managed Care October 2000	Diabetes Cases Up 33 Percent In Just 8 Years In findings that are likely to have serious implications for treatment-costs, adult incidence of diabetes rose 33 percent from 1990 to 1998, according to the U.S. Centers for Disease Control...
The Motley Fool July 8, 2008 Brian Lawler	Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards.
The Motley Fool September 30, 2011 Brian Orelli	A Drug Market That's 366 Million Strong Diabetes drugs have potential.
Managed Care February 2004	Improving Oral Pharmacologic Treatment And Management of Type 2 Diabetes New oral treatment options and outcome measures may help patients with type 2 diabetes to achieve better results while reducing associated costs.
Managed Care July 2005	Cost being equal, consumers prefer older drugs Seven out of 10 consumers would prefer a drug that had been on the market for 10 years or more, compared to a newer drug, even if the copayments were equal. This could be a sign that consumers are more inclined to start using generic medications.
The Motley Fool June 28, 2010 Luke Timmerman	Orexigen Drug Shows Potential as "Two-Fer" Against Obesity and Diabetes Orexigen's latest drug aims at treating both diabetes and obesity.
The Motley Fool November 5, 2007 Brian Lawler	Follow the Trend With Novo Nordisk The future is bright for Danish drugmaker Novo Nordisk. The worldwide leader in diabetes treatments turns in another good quarter.
Nursing Management January 2012 Lawrence et al.	Type 2 Diabetes: Growing to Epic Proportions Affecting all age groups and all aspects of a person's life, diabetes is a major public health issue worldwide, requiring lifelong behavioral and lifestyle changes and support.
The Motley Fool June 29, 2010 Brian Orelli	Diabetes Drug Development Pops and Drops When companies present at a major meeting, there's bound to be both.
Chemistry World December 20, 2013 Patrick Walter	AstraZeneca shells out $4.1bn for diabetes business AstraZeneca has agreed to pay Bristol-Myers Squibb up to $4.1 billion for its share of the pharma giants' diabetes joint venture.
The Motley Fool April 15, 2011 Luke Timmerman	Amylin, Alkermes Shares Jump as EU Regulators Recommend Diabetes Drug Will this drug be approved in Europe?
Managed Care May 2007 Rachel M. Renshaw	Keys to Diabetes Control? Patience, Persistence, and Perseverance Careful attention to a comprehensive treatment plan could forestall or prevent the need to add drugs and costs to a patient's regimen.
Managed Care June 2006	More Young Adults Prescribed ADHD Drugs The number of adults ages 20 to 44 prescribed attention deficit hyperactivity disorder medications increased about 140% from 2000 to 2005. This was even faster growth than the 82% reported for children.
The Motley Fool January 21, 2010 Brian Orelli	Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really?
The Motley Fool June 23, 2010 Brian Orelli	Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise.
BusinessWeek January 21, 2010 John Carey	Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes.
Pharmaceutical Executive August 1, 2008 Gayle Lorenzi et al.	Spanning the Treatment Gap How a diabetes field team helped docs overcome the treatment gap.
AskMen.com April 29, 2001 Joshua Levine	Do You Have Diabetes? Diabetes is not contagious; people cannot "catch" it from one another. However, certain factors can increase one's risk of developing the disease...
The Motley Fool October 31, 2006 Brian Lawler	Novo Nordisk Still Knows Sales There's more competition in diabetes care now, but the Danish pharmaceutical is thriving. Investors, take note.
Managed Care October 2004 Martin Sipkoff	Not So Much of a Reach: Let Sick Pay Less for Drugs The idea is radical and simple: Those who need medication the most should pay the least. There is evidence that this is cost-effective.
Managed Care June 2004	Use of Attention-Deficit Medications Surges 369 Percent in Children Under 5 ADHD medication spending for pediatric patients outpaces antibiotics, allergy, and asthma treatments.
Managed Care May 2006 Fadia T. Shaya & Deshpande	New Treatment Approaches To Diabetes The goal of diabetes management is maintaining glycemic control while targeting quality of life improvements.
Pharmaceutical Executive October 1, 2005	Changing Diabetes An interview with Novo Nordisk's president of U.S. operations Martin Soeters on how a nation that leads the world in diabetes research does such a poor job of treating it. Here, he offers some solutions.
American Family Physician November 1, 2000	Diabetes: How Do I Know if I Have it? Diabetes is a disease that occurs when your body doesn't make enough of a hormone called insulin, or if your body doesn't use insulin the right way. If left untreated, it may result in blindness, heart attacks, strokes, kidney failure and amputations...
Managed Care August 2004 Alan Lotvin	Specialty Pharmacy Presents Unique Set of Challenges Only a small percent of a typical health plan's population takes medicine for conditions outside the generalist's scope. But it's a big portion of the drug bill.
BusinessWeek May 27, 2010 Michelle Cortez	Karo Bio's Prescription: Cheaper Drug Approval A Swedish company seeks a lower-cost review for its cholesterol drug.
Managed Care July 2007	The Formulary Files Chronic disease treatments contribute significantly to spending growth.
American Family Physician October 15, 2003	Diabetes and Heart Disease I have diabetes -- why should I worry about heart disease?... What are the ABCs of diabetes?... Where can I learn more about diabetes and heart disease?... What can I do to reduce my risk for heart disease?
Chemistry World July 16, 2010 Matt Wilkinson	Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US.
The Motley Fool January 31, 2007 Brian Lawler	No Sickness for Amylin Sales of the drugmaker's type-2 diabetes drugs showed solid growth. Investors, take note.
The Motley Fool January 4, 2011 Brian Orelli	A Drug Deal an Options Trader Would Love XOMA licenses its diabetes drug, but retains rights to buy it back.
American Family Physician April 15, 2004	Taking Steps to Prevent Type 2 Diabetes Information on type 2 diabetes: detection, who is at risk, and prevention.
Managed Care July 2007 Martin Sipkoff	Lowering Copayments Can Improve Quality of Chronic Disease Care Employers and health plans are starting to see the advantage of what has been termed evidence-based benefit design.
Managed Care May 2006 Frank Diamond	It's Hard To Not Take Diabetes Personally The costs are of managing diabetes are ballooning and incidence is up and going to go higher.
The Motley Fool November 3, 2009 Brian Orelli	Amylin Scores a Hat Trick Amylin Pharmaceuticals got a triple dose of good news over the weekend.
CIO September 26, 2013 Stephanie Overby	Big Data Project Cuts Prescription Costs Express Scripts analytics portal helps doctors prescribe more cost-effective medicines.
The Motley Fool February 8, 2011 Esterhuizen & Sellitti	Battle of the Bulge: Biotech Takes on Obesity and Diabetes Will recent advances in pharmaceutical research revolutionize the weight loss industry? It's still early days, but here are some of the stocks to watch.
The Motley Fool May 31, 2011 Brian Orelli	Profit From This Growing Drug Trend Cancer drugs press on.
Managed Care May 2006 Martin Sipkoff	Health Plans Are Ill-Prepared for Looming Diabetes Epidemic The problem is outpacing insurers' resources and perhaps even their commitment. Can the chronic care model help?
BusinessWeek April 30, 2010 Drew Armstrong	The Lobbying for Death by Diabetes How a health-reform provision may help spur sales of insulin.
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
The Motley Fool August 26, 2010 Brian Orelli	Drug Prices Up, but Don't Read Too Much Into It AARP is out with its annual report on the cost of medications, and it's more of the same: bad news if you're a consumer, but good news if you're invested in drugmakers.
Chemistry World September 24, 2010 Andrew Turley	End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use.
The Motley Fool March 3, 2011 Brian Orelli	Amylin Comes Up Snake Eyes Amylin Pharmaceuticals and partners Eli Lilly and Alkermes announced results of their head-to-head clinical trial comparing Bydureon with Novo Nordisk's diabetes drug Victoza.
BusinessWeek December 22, 2003 Arlene Weintraub	Big Pharma Looks Beyond Insulin Researchers may be on the verge of major new treatments for diabetes and obesity.